The 67% regain stat scares everyone. Here's what it actually means, why it's misleading, and the evolving strategies for maintaining your results.
The scariest number in GLP-1 therapy: patients who abruptly stopped semaglutide in the STEP-1 extension trial regained approximately two-thirds of the weight they'd lost within one year. This has been weaponized by critics of GLP-1 therapy to argue that these drugs don't "really" work — that they're just temporary fixes.
That framing is misleading. Here's why.
The STEP-1 extension data measured what happens when patients abruptly discontinue semaglutide at week 68 with no structured maintenance protocol. They stopped the medication and were essentially told "good luck." Of course they regained weight. The pharmacological appetite suppression was removed with nothing to replace it.
This is like measuring what happens when you stop taking blood pressure medication without any lifestyle changes. Yes, your blood pressure goes back up. That doesn't mean the medication doesn't work. It means the condition being treated requires ongoing management.
Obesity is a chronic condition with hormonal, neurological, and metabolic drivers. Removing pharmacological treatment without a maintenance strategy produces predictable results — just as it does for diabetes, hypertension, or any other chronic disease.
The most evidence-supported maintenance approach: continue GLP-1 therapy at a reduced dose indefinitely. Just as you might stay on a statin long-term for cardiovascular protection, staying on a lower dose of GLP-1 medication maintains appetite regulation, metabolic improvement, and cardiovascular benefit.
Many providers are now prescribing maintenance protocols at 50–75% of the therapeutic dose. For men who achieved their weight loss at 2.4mg semaglutide weekly, maintenance at 1.0mg or 1.7mg may be sufficient to prevent significant regain while reducing cost and side effects.
The cost argument is relevant: maintenance at a lower dose is cheaper. If your treatment dose costs $200/month and your maintenance dose is half that, the long-term financial commitment becomes more sustainable.
An emerging approach: cycling between periods on and off GLP-1 medication, using behavioral and metabolic markers to determine when to resume. This is less studied than continuous use but reflects how many patients actually use the medication in practice.
The framework: complete a 12–18 month treatment phase. Gradually taper (over 4–8 weeks, not abrupt discontinuation). Monitor weight, appetite, and metabolic markers during the off period. If weight regain exceeds 5–10% of lost weight, resume medication at the maintenance dose.
This requires disciplined monitoring and honest self-assessment. It works best for men who've successfully established the lifestyle habits (training, protein intake, sleep) during treatment and can maintain them independently.
The strongest predictor of maintained weight loss — with or without continued medication — is whether the lifestyle changes established during treatment become permanent habits:
Resistance training 3–4× per week. The muscle mass you preserved (or built) during treatment maintains a higher metabolic rate. Keep training. If you stop, metabolic rate drops and regain accelerates. This is the single most impactful maintenance behavior.
Protein-first eating. Even without GLP-1 appetite suppression, maintaining 1.2g/kg daily protein intake supports muscle mass, satiety, and metabolic rate. The protein habit formed during treatment should persist afterward.
Regular weigh-ins. Men who weigh themselves weekly and respond to early regain (5+ lbs above target) maintain weight more successfully than those who avoid the scale. Catching regain early — when 5 lbs needs to come off instead of 30 — is dramatically easier.
Sleep hygiene. Maintain the 7–9 hour sleep schedule that supports hormonal health and metabolic function.
Alcohol moderation. If GLP-1 therapy reduced your alcohol intake, work to maintain that moderation after medication ends. The caloric and hormonal benefits of reduced alcohol persist independently.
Men have a specific advantage in weight maintenance that women don't share: the testosterone restoration from GLP-1 therapy may persist after medication discontinuation as long as significant visceral fat regain doesn't occur.
If you lost enough visceral fat to normalize testosterone (the 77% normalization rate), and you maintain that fat loss through training and diet, your testosterone stays elevated. Higher testosterone supports muscle mass and metabolic rate, creating a self-reinforcing maintenance loop.
The key: don't let visceral fat re-accumulate. Visceral fat regain → aromatase increase → testosterone decline → metabolic slowdown → further weight gain. Break the loop early with the monitoring and response system described above.
Realistically, most men will follow some combination of strategies: maintain a lower dose of GLP-1 medication for 6–12 months after reaching target weight, then attempt a supervised taper. Some will successfully maintain off-medication with lifestyle alone. Others will need ongoing low-dose medication indefinitely — and that's OK. It's chronic disease management, not failure.
The men who maintain best share three characteristics: they continued resistance training, they maintained high protein intake, and they monitored their weight weekly with a predetermined action threshold (e.g., "if I gain 8 lbs above target, I resume medication").
All-inclusive pricing works for both treatment and maintenance phases. Discuss reduced-dose maintenance with your provider as you approach target weight.
Check Eligibility →SHED's coaching add-on is particularly valuable during the treatment-to-maintenance transition, when behavioral habits need to replace pharmacological support.
Check Eligibility →